Every day, our scientists tackle challenging problems like the scalable synthesis of complex molecules. In this latest publication in Science Magazine, we share how we’re using #biocatalysis to manufacture orally available macrocyclic peptides. Learn more: go.msd.com/~q3y

Today, MSD completed the acquisition of Terns Pharmaceuticals, further strengthening our #oncology portfolio and reinforcing our focus on science‑driven innovation. Learn more: go.msd.com/~0bd

Join us today at 9 a.m. ET to learn more about our Q1 2026 #earnings: go.msd.com/~qh7

Our Q1 2026 #earnings results are live. Check out our full financial summary and key highlights: go.msd.com/~uw0

We’re proud to partner with Google Cloud to help shape the future of biopharmaceutical innovation with AI-enabled enterprise transformation. This collaboration is about unlocking new value: accelerating discovery, modernizing how we work and empowering our teams to focus on the highest-impact science and solutions for patients. Learn more about the landmark partnership: go.msd.com/~7q2

Today we announced the initiation of a pivotal Phase 2b/3 trial for the treatment of patients with neovascular age-related macular degeneration (#wetAMD). Learn more: go.msd.com/~n4o #ophthalmology

We’re sharing Phase 3 results of our investigational oral macrocyclic peptide. Learn more: go.msd.com/~lx0

Today, we announced an agreement to acquire Terns Pharmaceuticals, adding a potential best-in-class candidate for the treatment of certain patients with chronic myeloid #leukemia (#CML) to our growing #hematology pipeline: go.msd.com/~dpo9lg

Join us today at 9 a.m. ET to learn more about our Q4 and full-year 2025 #earnings: go.msd.com/~3kr

Our Q4 and full-year 2025 #earnings results are live. Check out our full financial summary and key highlights: go.msd.com/~vk8

Today, we announced the completion of the acquisition of Cidara Therapeutics, diversifying our pipeline with a novel late-phase antiviral candidate being evaluated for the prevention of symptomatic influenza in certain individuals at high risk of complications. Learn More. msd.gl/4svGbC3

Today, we signed a most favored nations agreement with the Trump administration. Addressing global pricing imbalances through a fair, value-based approach is essential, and this agreement helps us do that responsibly, while improving access for U.S. patients at an affordable price. A key component of this agreement is ensuring access to our investigational oral PCSK9 inhibitor being evaluated in patients with elevated cholesterol. Once approved, this medicine will be available through a direct-to-patient program making it easier to get at affordable prices. Over time we hope to be able to broaden access to this important medicine globally at affordable prices. msd.gl/492OKLE

We’re excited to share new data from our neuroscience pipeline at CTAD 2025, including results for two #AlzheimersDisease candidates. The U.S. FDA has granted Fast Track Designation to one of our candidates for the treatment of Alzheimer's. Learn more: msd.gl/4q0zeXV

Today, we announced an agreement to acquire Cidara Therapeutics, Inc., diversifying our respiratory portfolio to include an investigational long-acting strain-agnostic antiviral agent. msd.gl/49U4Ycb

Today, we announced a strategic funding agreement with Blackstone, positioning our company to advance development of an investigational antibody-drug conjugate targeting TROP2 while we continue to advance our broad and expansive pipeline. Read more: msd.gl/4nAqvtG

Join us today at 9 a.m. ET to learn more about our Q3 2025 #earnings: msd.gl/4oPTGdr

Our Q3 2025 #earnings results are live. Check out our full financial summary and key highlights: msd.gl/3JjUpo1

We are pleased to announce that we’ve completed our acquisition of @VeronaPharma, bringing talented new colleagues into our company and strengthening our cardio‑pulmonary footprint. Learn more: msd.gl/3IT5o7E

Join us today at 9 a.m. ET to learn more about our Q2 2025 #earnings: msd.gl/4mf258C